Rosetta Genomics Ltd. (ROSG) Inks Agreements with Two Israel-based Research Centers
Rosetta Genomics Ltd., a leading developer and provider of microRNA-based molecular diagnostics, today announced it has signed two new agreements pertaining to the development and validation of microRNA-based diagnostics related to its Gen 3 products. The agreements with Israel-based Tel Hashomer Medical Research Infrastructure and Services Ltd. and Israel-based Carmel Medical Center are part of what Rosetta Genomics called an “integral part” to its product development process. The Gen 3 tests will analyze cardiovascular indications, neurodegenerative diseases, women's health and early detection of certain cancers, and are designed to leverage the capabilities and samples to identify microRNA biomarkers extracted from…